SCHEMBL31635534

SCHEMBL31635534

N#Cc1ccc(-c2cncc3c2OCCN3C(=O)C2CN(C(=O)c3cccc(F)c3)C2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 2/20 0.42
▸ CYP3A4 P08684 6/20 0.41
▸ USP2 O75604 4/20 0.41
▸ CYP2D6 P10635 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ABL1 P00519 1/20 0.39
▸ BCR P11274 1/20 0.39
▸ UCHL1 P09936 2/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ HSD11B1 P28845 1/20 0.38
▸ GRM5 P41594 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CYP11B1 P15538 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30774559 0.90 USP30 (0.41) USP30ALDH1A1UCHL1KDM1APAX8
SCHEMBL30774894 0.90 CYP3A4 (0.42) USP30CYP3A4USP2CYP2D6ALDH1A1
SCHEMBL30774031 0.89 ABL1 (0.42) USP30ALDH1A1ABL1BCRUCHL1
SCHEMBL31635537 0.87 USP30 (0.43) USP30UCHL1HPGDCYP11B1CYP11B2
SCHEMBL30774590 0.85 USP30 (0.42) USP30CYP3A4USP2CYP2D6ALDH1A1
SCHEMBL30774439 0.84 CHRM1 (0.46) USP30UCHL1SMN1; SMN2CYP11B1CYP11B2
SCHEMBL30773974 0.83 PTGER4 (0.42) USP30CYP3A4USP2CYP2D6ALDH1A1
SCHEMBL30774432 0.81 USP30 (0.42) USP30ALDH1A1UCHL1HPGDCYP11B2
SCHEMBL30774398 0.81 USP30 (0.46) USP30ALDH1A1UCHL1HPGDKDM1A
SCHEMBL30774512 0.81 USP30 (0.45) USP30UCHL1GRM5CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US claimed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP claimed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 USP30 728/4885CYP3A4 184/4885USP2 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback